Gilead's New Hep B Treatment Shows Safety Benefit But Is It Enough?
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. is to file for US and EU approval this quarter of its once-daily treatment for hepatitis B, tenofovir alafenamide (TAF) 25 mg, on the basis of two newly reported Phase III studies.
You may also be interested in...
From Solanezumab To Solithromycin: What To Watch For In Q4
Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.